A detailed history of Krensavage Asset Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Krensavage Asset Management, LLC holds 1,677,393 shares of EXEL stock, worth $57.2 Million. This represents 17.31% of its overall portfolio holdings.

Number of Shares
1,677,393
Previous 1,566,140 7.1%
Holding current value
$57.2 Million
Previous $37.2 Million 1.42%
% of portfolio
17.31%
Previous 16.48%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $2.26 Million - $2.64 Million
111,253 Added 7.1%
1,677,393 $37.7 Million
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $6.72 Million - $7.97 Million
-332,939 Reduced 17.53%
1,566,140 $37.2 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $1,386 - $1,737
-72 Reduced -0.0%
1,899,079 $45.6 Million
Q3 2023

Nov 14, 2023

SELL
$19.04 - $22.74 $4.47 Million - $5.33 Million
-234,552 Reduced 10.99%
1,899,151 $41.5 Million
Q2 2023

Aug 11, 2023

SELL
$18.17 - $20.48 $39,338 - $44,339
-2,165 Reduced 0.1%
2,133,703 $40.8 Million
Q1 2023

May 15, 2023

SELL
$16.3 - $19.41 $35,387 - $42,139
-2,171 Reduced 0.1%
2,135,868 $41.5 Million
Q4 2022

Feb 15, 2023

BUY
$14.96 - $17.39 $4.74 Million - $5.51 Million
316,564 Added 17.38%
2,138,039 $34.3 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $4.93 Million - $7.01 Million
314,590 Added 20.88%
1,821,475 $28.6 Million
Q2 2022

Aug 16, 2022

SELL
$17.44 - $23.16 $410,206 - $544,746
-23,521 Reduced 1.54%
1,506,885 $31.4 Million
Q1 2022

May 17, 2022

SELL
$17.03 - $22.67 $454,922 - $605,583
-26,713 Reduced 1.72%
1,530,406 $34.7 Million
Q4 2021

Feb 15, 2022

BUY
$15.84 - $21.88 $8.82 Million - $12.2 Million
557,119 Added 55.71%
1,557,119 $28.5 Million
Q3 2021

Nov 16, 2021

BUY
$16.3 - $21.14 $16.3 Million - $21.1 Million
1,000,000 New
1,000,000 $21.1 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Krensavage Asset Management, LLC Portfolio

Follow Krensavage Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krensavage Asset Management, LLC with notifications on news.